Now for O4S1, we’ve actually got a choice. We’ve taken that along to the point where we’re comfortable we could make a choice whenever we wanted to. They are produced with different manufacturing technologies, which we — they’re out there. We would just have select how we wanted to do it. So we’re actually at the stage now where we’re talking business terms and that would be John Sharky. I don’t know that we’re going to share any details on that, but that one’s ready to go. We have another candidate or another research level product where I think we would know exactly where we would go, but it’s still in the mouse model. It’s second kind of a secondary approach, more of a universal COVID, but we’re not focusing on that as much as the O4S1.
So we’re there, but I think you would have to say that each one of these is likely to be a specific paired system. It would be great if we could find a single manufacturer and a single cell line that would do it all for us. And I’m hopeful maybe we’ll get lucky. But realistically, we have seen variation. And so we we’re doing the right stuff, each of the steps for each product. So these lead product we’re ready, we could make a decision.
Jeffrey Kraws: Perfect. That would be a better approach and compared to with what you said. One final question is, you’re seeing a lot of interest and a lot of movement out there amongst pharma companies, at least in our coverage of pharma. We’re seeing still strong interest in partnering with novel companies with unique and differentiated technologies that are game changers. You’re still seeing a lot of interest for potential partners?
John Sharkey: Yes, I’ll take that 1. Yes. Hey, Jeff. Thanks for the question. So, actually, I was in Basel earlier this week at the Bio Spring European Partnering meeting. And as you know, we started discussions with companies last year with a Bio. And what I can say is that I’m seeing more and more interest in — once people understand the mission we’re trying to work in. I mean, the reality is world’s gotten a little tired of COVID and the general population. And so, I’m often asked, do we need another COVID vaccine? But when you kind of lay out where we’re working in the immune compromise, that the current vaccine just are not adequate to protect these people. These people are risk of people engaged. Now, are we at the point where I could say if somebody’s going to snap it up?
I can’t say that, but I will say that people are engaging with us and following up with us on stuff. And so, I think where we’re working, we’re succeeding in convincing people. There is a real need in this space and that there’s a lot of attractive options in this space. And that these are patients who are normally underactive treatment. They’re being medically managed. They’re being managed by specialists, which means you have smaller field forces to detail them. They’re easier to identify and get to. There’s a lot of positives from the commercial side and working in this space.
Jeffrey Kraws: I appreciate your . Thanks for taking the questions. Keep up the good work. Thank you.
Operator: Thank you. There are no further questions at this time. I’ll hand the floor back to Mark Reynolds for closing remarks.
Mark Reynolds: Yes, thank you. I just want to conclude the call by thanking everybody for participating. Your interest really is greatly appreciated by all of us. And I’ll say that our focus for this year, for 2023 is on execution, on reporting updates and progress for our Gedeptin and our CMO4S1 clinical programs, as well as the other odd development programs we have underway. And for all of us, it is a great pleasure serving the shareholders as I say that truthfully in being part of this team. So with that, I’ll conclude and I’ll just tell everybody, have a good day. Thank you.
Operator: Thank you. This concludes today’s conference. All parties may disconnect. Have a great evening.
